When we run for a bus or reach for our phones, our bodies instantly translate the oxygen we breathe and our energy reserves into coordinated movement. We don’t have to give it a second thought. However, this is different for people with Pulmonary Arterial Hypertension (PAH). It may be hard to believe, but for people living with PAH simple everyday tasks can feel as tough as climbing Mount Everest.
Advances in the diagnosis and management of PAH have resulted in significant improvements in outcomes for patients with this devastating and progressive disease. However, because of the non-specific nature of its symptoms, prompt and accurate diagnosis of PAH as a rare disease remains a challenge. Scientists and innovators today are developing the next generation of diagnostics & treatments for PAH by leveraging technologies such as stem cell therapy, gene therapy, miRNA technology, and more. But how close are we to breakthrough solutions and what are the latest developments in the space?
Join Johnson & Johnson Innovation, JLABS & Actelion Pharmaceuticals Canada Inc., a Janssen pharmaceutical company of Johnson & Johnson, as we bring together innovators advancing PAH therapies and their new approaches to treatments & diagnostics. These scientific experts will share their data and insights to advance our understanding of this space, and the unique challenges they face in PAH.